Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs

NACompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

July 30, 2018

Study Completion Date

September 29, 2022

Conditions
Atrial Septal Defect
Interventions
DEVICE

GORE® CARDIOFORM ASD Occluder

Percutaneous Atrial Septal Defect Closure

Trial Locations (22)

10029

Mount Sinai Medical Center, New York

10032

Columbia University Medical Center/New York Presbyterian Hospital, New York

19014

Children's Hospital of Philadelphia, Philadelphia

28203

Atrium Health, Charlotte

30322

Children's Healthcare at Egleston, Atlanta

33155

Nicklaus Children's Hospital, Miami

43205

Nationwide Children's Hospital, Columbus

44195

Cleveland Clinic Foundation, Cleveland

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Riley Hospital for Children, Indianapolis

48109

University of Michigan, Ann Arbor

48201

Children's Hospital of Michigan, Detroit

55905

Mayo Clinic - Rochester, Rochester

77030

Texas Children's Hospital, Houston

80218

The Children's Hospital of Colorado, Aurora

84113

University of Utah, Salt Lake City

85016

Phoenix Children's Hospital, Phoenix

90095

University of California-Los Angeles, Los Angeles

98105

Children's Hospital & Regional Medical Center, Seattle

06520

Yale University School of Medicine, New Haven

02114

Massachusetts General Hospital, Boston

02115

Children's Hospital Boston, Boston

All Listed Sponsors
lead

W.L.Gore & Associates

INDUSTRY

NCT02985684 - Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs | Biotech Hunter | Biotech Hunter